Protiva lands fee in Merck RNAi tech deal

Canada's Protiva Biotherapeutics dropped litigation against Merck subsidiary Sirna Therapeutics when it inked a deal to share its RNAi technology with the pharma giant. Protiva has developed Stable Nucleic Acid-Lipid Particles, or SNALPs, that are used to deliver interfering RNA to cells. Protiva landed an undisclosed upfront fee and a royalty share on any new therapies that use the technology.

- see this release

Related Articles:
Merck to shell out $1.1B for Sirna. Report
Sirna pushing RNAi field. Report
A billion-dollar lesson in RNAi economics. Report

Read more on: Merck | Sirna | RNAi

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.